Stock overview
Perspective Therapeutics, Inc. (CATX)
$2.91-1.36%Aft $2.96 (+1.72%)Market cap $331.9M
Stock Scorer
Scoring…
Analyst consensus
$12.93
- Analysts15
- Implied upside+344.4%
- Target range$6.00 to $18.00
Analyst estimates are opinions, not forecasts of what the stock will do.
SEC filings
| Form | Filed | Description |
|---|---|---|
| SCHEDULE 13G | July 20, 2026 | View on EDGAR |
| 8-K | July 1, 2026 | 8-K |
| SCHEDULE 13G | June 30, 2026 | View on EDGAR |
| 8-K | June 1, 2026 | 8-K |
| 8-K | May 27, 2026 | 8-K |
| 8-K | May 22, 2026 | 8-K |
| SCHEDULE 13G/A | May 12, 2026 | View on EDGAR |
| 10-Q | May 11, 2026 | 10-Q |
Our CATX coverage
Frequently asked questions
What do analysts expect for CATX?
15 analysts cover Perspective Therapeutics, Inc. (CATX). The consensus rating is Strong buy and the average price target is $12.93, in a range of $6.00 to $18.00.
Are insiders buying or selling CATX?
We have no qualifying Form 4 insider purchases or sales on record for Perspective Therapeutics, Inc. (CATX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see CATX SEC filings?
Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G filed July 20, 2026.
Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.